Proteomic profiling reveals sub proteomes of the human placenta
We describe an unbiased proteomic mapping analysis to investigate how the placental proteome changes throughout the organ. A transverse slice of a human placenta was sectioned into 1 × 1cm samples. Sections were analysed using label free proteomics. Analysis revealed two distinct sub-proteomes that did not have anatomical significance. One had a muscular proteome and the other had distinct immunomodulation functions. (Source: Placenta)
Source: Placenta - September 29, 2017 Category: Reproduction Medicine Authors: Wendy E. Heywood, Rhian-Lauren Preece, Jeremy Pryce, Jenny Halqvist, Robert Clayton, Alex Virasami, Kevin Mills, Neil J. Sebire Tags: Technical note Source Type: research
Title Page/Editorial Board
(Source: Placenta)
Source: Placenta - September 27, 2017 Category: Reproduction Medicine Source Type: research
IFPA Pages
(Source: Placenta)
Source: Placenta - September 27, 2017 Category: Reproduction Medicine Source Type: research
Expression of AQUAPORIN-3 (AQP3) in placentas from pregnancies complicated by preeclampsia
Recently, we have reported that the blocking of AQP3 abrogates the apoptotic response of the trophoblast. Since trophoblast apoptosis is exacerbated in preeclampsia, we hypothesized that placental AQP3 is increased in these placentas in order to trigger the programmed cell death. Here, we examined mRNA levels, protein expression and localization of AQP3 in placentas from pregnancies complicated by preeclampsia and against what we expected, we found that AQP3 expression was significantly reduced, both at protein and mRNA levels, compared to normal placentas. (Source: Placenta)
Source: Placenta - September 26, 2017 Category: Reproduction Medicine Authors: Natalia Szpilbarg, Alicia E. Damiano Tags: Short communication Source Type: research
Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus.Maternal uterine artery gene therapy presents a promising treatment strategy for IUGR, with the use of adenoviral vectors encoding for proteins such as Vascular Endothelial Growth Factor (VEGF) demonstrating improvements in fetal growth and neon...
Source: Placenta - September 26, 2017 Category: Reproduction Medicine Authors: Anna L. David Source Type: research
